These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 20708340

  • 1. Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments.
    Raskin S, Durst R.
    Med Hypotheses; 2010 Dec; 75(6):544-6. PubMed ID: 20708340
    [Abstract] [Full Text] [Related]

  • 2. [Successful treatment of depression in a Parkinson disease patient with bupropion].
    Leentjens AF, Verhey FR, Vreeling FW.
    Ned Tijdschr Geneeskd; 2000 Nov 04; 144(45):2157-9. PubMed ID: 11086491
    [Abstract] [Full Text] [Related]

  • 3. Treatment of panic disorder with bupropion in a patient with Parkinson's disease.
    Gebhardt S, Röttgers H, Bäcker A, Schu U, Krieg JC.
    J Clin Pharm Ther; 2008 Oct 04; 33(5):575-7. PubMed ID: 18834374
    [Abstract] [Full Text] [Related]

  • 4. Bupropion for depression in schizophrenia.
    Englisch S, Inta D, Eer A, Zink M.
    Clin Neuropharmacol; 2010 Oct 04; 33(5):257-9. PubMed ID: 20852411
    [Abstract] [Full Text] [Related]

  • 5. Dopamine receptor agonists and depression in Parkinson's disease.
    Picillo M, Rocco M, Barone P.
    Parkinsonism Relat Disord; 2009 Dec 04; 15 Suppl 4():S81-4. PubMed ID: 20123564
    [Abstract] [Full Text] [Related]

  • 6. Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor.
    Dhir A, Kulkarni SK.
    Eur J Pharmacol; 2007 Jul 30; 568(1-3):177-85. PubMed ID: 17509558
    [Abstract] [Full Text] [Related]

  • 7. [Selective noradrenaline-dopamine reuptake inhibition (SNDRI). More latitude for antidepressive therapy].
    MMW Fortschr Med; 2007 May 21; 149 Suppl 2():88-9. PubMed ID: 17724976
    [No Abstract] [Full Text] [Related]

  • 8. [Neuropsychiatric disorders in Parkinson's disease].
    Noé-Sebastián E, Irimia-Sieira P, Pomares-Arias E, Martínez-Vila E, Luquin-Piudo MR.
    Rev Neurol; 2007 May 21; 32(7):676-81. PubMed ID: 11391498
    [Abstract] [Full Text] [Related]

  • 9. Review of bupropion for smoking cessation.
    Richmond R, Zwar N.
    Drug Alcohol Rev; 2003 Jun 21; 22(2):203-20. PubMed ID: 12850907
    [Abstract] [Full Text] [Related]

  • 10. [The relevance of dopamine agonists in the treatment of depression].
    Clausius N, Born C, Grunze H.
    Neuropsychiatr; 2009 Jun 21; 23(1):15-25. PubMed ID: 19272288
    [Abstract] [Full Text] [Related]

  • 11. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ, Kaplitt MG, Stern MB, Eidelberg D.
    Hum Gene Ther; 2001 Aug 10; 12(12):1589-91. PubMed ID: 11529246
    [Abstract] [Full Text] [Related]

  • 12. Bupropion in the treatment of depression in Parkinson's disease.
    Załuska M, Dyduch A.
    Int Psychogeriatr; 2011 Mar 10; 23(2):325-7. PubMed ID: 20809995
    [Abstract] [Full Text] [Related]

  • 13. Wellbutrin versus generic bupropion.
    Med Lett Drugs Ther; 2008 Jul 14; 50(1290):54-5. PubMed ID: 18617874
    [No Abstract] [Full Text] [Related]

  • 14. Depressive symptom profile in Parkinson's disease: a comparison with depression in elderly patients without Parkinson's disease.
    Ehrt U, Brønnick K, Leentjens AF, Larsen JP, Aarsland D.
    Int J Geriatr Psychiatry; 2006 Mar 14; 21(3):252-8. PubMed ID: 16477585
    [Abstract] [Full Text] [Related]

  • 15. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.
    Jain AK, Kaplan RA, Gadde KM, Wadden TA, Allison DB, Brewer ER, Leadbetter RA, Richard N, Haight B, Jamerson BD, Buaron KS, Metz A.
    Obes Res; 2002 Oct 14; 10(10):1049-56. PubMed ID: 12376586
    [Abstract] [Full Text] [Related]

  • 16. A case of treating cathinone dependence and comorbid depression using bupropion.
    Lev-Ran S.
    J Psychoactive Drugs; 2012 Oct 14; 44(5):434-6. PubMed ID: 23457895
    [Abstract] [Full Text] [Related]

  • 17. Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder.
    Hewett K, Chrzanowski W, Jokinen R, Felgentreff R, Shrivastava RK, Gee MD, Wightman DS, O'Leary MC, Millen LS, Leon MC, Briggs MA, Krishen A, Modell JG.
    J Psychopharmacol; 2010 Apr 14; 24(4):521-9. PubMed ID: 19164492
    [Abstract] [Full Text] [Related]

  • 18. Psychopharmacology of smoking cessation in patients with mental illness.
    Selby P.
    J Psychiatry Neurosci; 2006 Sep 14; 31(5):360. PubMed ID: 16951737
    [No Abstract] [Full Text] [Related]

  • 19. ECT for Parkinson's disease.
    Popeo D, Kellner CH.
    Med Hypotheses; 2009 Oct 14; 73(4):468-9. PubMed ID: 19660875
    [Abstract] [Full Text] [Related]

  • 20. Depressive illness in Parkinson's disease--indication of a more advanced and widespread neurodegenerative process?
    Pålhagen SE, Carlsson M, Curman E, Wålinder J, Granérus AK.
    Acta Neurol Scand; 2008 May 14; 117(5):295-304. PubMed ID: 18279483
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.